Extensive adaptive immune response of AAVs and Cas proteins in non-human primates
Y. Chen, P. Xiao, R. Bai, T. Zhang, Y. Zhou, Z. Zhou, Y. Zhuo, N. Gong, J. Liu, S. Ren, R. Wu, B. Shen, S. Li, Y. Niu, W. Ji
Abstract
The CRISPR-mediated Cas system is the most widely used tool in gene editing and gene therapy for its convenience and efficiency. Delivery of the CRISPR system by adeno-associated viruses (AAVs) is currently the most promising approach to gene therapy. However, pre-existing adaptive immune responses against CRISPR nuclease (PAIR-C) and AAVs has been found in human serum, indicating that immune response is a problem that cannot be ignored, especially for in vivo gene correction. Non-human primates (NHPs) share many genetic and physiological traits with human, and are considered as the bridge for translational medicine. However, whether NHPs have same PAIR-C status with human is still unknown. Here, macaques (rhesus and cynomolgus), including normal housed and CRISPR-SpCas9 or TALENs edited individuals, were used to detect PAIR-C which covered SaCas9, SpCas9, AsCas12a and LbCas12a. Dogs and mice were also detected to expand the range of species. In addition, pre-existing adaptive antibodies to AAV8 and AAV9 were performed against macaques of different ages. The results showed that adaptive immunity was pre-existing in the macaques regardless of Cas proteins and AAVs. These findings indicate that the pre-existing adaptive immune of AAV-delivered CRISPR construction and correction system should be concerned for in vivo experiments.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans
C. T. Charlesworth, P. S. Deshpande, … M. H. Porteus·bioRxiv·Jan 5, 2018
- Single-AAV CRISPR editing of skeletal muscle in non-human primates with NanoCas, an ultracompact nuclease
Benjamin J. Rauch, Aaron DeLoughery, … Lucas B. Harrington·bioRxiv·Jan 29, 2025
- In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in
Jack M.P. Castelli, Katrina Poljakov, … Jennifer E. Adair·bioRxiv·May 2, 2025
- AAV-delivered CRISPR-Cas9 elicits persistent retinal immune responses compared with transient responses to RNP
Juliette Pulman, Duohao Ren, … Sylvain Fisson·bioRxiv·Dec 14, 2025
- In vivo selection in non-human primates identifies superior AAV capsids for on-target CSF delivery to spinal cord
K. S. Hanlon, M. Cheng, … C. A. Maguire·bioRxiv·Sep 13, 2023
- Viral delivery of compact CRISPR-Cas12f for in vivo gene editing applications
Allison M. Sharrar, Zuriah A. Meacham, … Michael W. Schelle·bioRxiv·Feb 6, 2024